Ahmedabad-based Zydus group on Wednesday announced a breakthrough in its research with Lipaglyn, a novel drug to treat Diabetic Dysilipidemia or Hypertriglyceridemia in Type II diabetes.
The drug has been approved for launch in India by the Drug Controller General of India (DGCI). “It is India’s first new chemical entity (NCE) to move from the laboratory to the market,” Pankaj Patel, Chairman and Managing Director, Zydus Cadila, told a press conference.
Lipaglyn will be launched in the third quarter of 2013-14 and the company has already initiated approvals in other markets. “We will first launch in emerging markets and then developed markets over the next 3-5 years,’’ Mr. Patel said. Zydus will enter marketing tie-ups to sell overseas.
Lipaglyn offers a novel action that offers lipid and glucose lowering effects in one molecule and is the first Glitazar to be approved anywhere in the world. “The product provides patients suffering from diabetic dyslipidemia the option of a once-daily oral therapy and has beneficial effect on both lipid parameters as well as glycemic control.’’ Ganesh Nayak, Executive Director and COO, said the company had yet to finalise the selling price.
